Azacitidine as maintenance therapy in pediatric <i>de novo</i> acute myeloid leukemia.

ABSTRACT:

Background

Relapse remains a major challenge in pediatric acute myeloid leukemia (AML), particularly in patients ineligible for hematopoietic stem cell transplantation (HSCT). Hypomethylating agents like azacitidine are hypothesized to target residual disease, but their efficacy and safety as maintenance therapy in de novopediatric AML require validation.

Methods

In this retrospective cohort study, 78 pediatric patients with de novoAML in remission after the C-HUANAN-AML 15 protocol were assigned to either azacitidine maintenance (n=27; subcutaneous 75 mg/m²/day, days 1-14 per cycle for 6 cycles) or observation (n=51) groups. Measurable residual disease (MRD) was monitored longitudinally via multiparameter flow cytometry (<0.1% threshold) and PCR for fusion tra

SUBMITTER: Wu C 

PROVIDER: S-EPMC12714944 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature